Van Rampelbergh, Jean
Achenbach, Peter
Leslie, Richard David
Kindermans, Martin
Parmentier, Frédéric
Carlier, Vincent
Bovy, Nicolas
Vanderelst, Luc
Van Mechelen, Marcelle
Vandepapelière, Pierre
Boitard, Christian
Article History
Received: 6 December 2023
Accepted: 11 June 2024
First Online: 21 June 2024
Declarations
:
: The study was conducted across multiple countries and institutions and was approved by all relevant ethics committees and national authorities. Belgium: Medical Ethics Committee UZ Brussel—Ref2017/122, Denmark: Capital Region of Denmark—Centre for Health—Scientific ethics Committee—Ref: H-17009698, France: Comité de Protection des Personnes Sud Méditerranée I—Ref 17 45, Germany: Technical University of Munich—Faculty of Medicine—Ethics Committee—Ref 128/17 Af, Lithuania: Lithuanian Bioethics Committee—Ref 2018–03–21 No. P-I 8–20/2, Sweden: Regional Ethical Review Board in Gothenburg—Ref 189–18, United Kingdom: London—Chelsea Research Ethics Committee—Ref 17/LO/0633. All patients signed informed consent before taking part in the study.
: The data of individual patients were de-identified and used for statistical analysis; no individual patient data are presented in the manuscript.
: JVR, VC, NB, LV, MVM, and PV are employees or contractors of Imcyse S.A., Liège, Belgium, and may hold stock options. MK and FP are employees of Ariana Pharmaceuticals SA. RDL’s institution received study funding and materials from Imcyse. RDL received honorarium from DMRR and took part in advisory boards for Diamyd and Provention. CB’s institutions received study funding and materials from Imcyse. PA declares no competing interests.